Jubilant Pharmova Receives USFDA Tentative Approval for Generic Pantoprazole Oral Suspension

Key Metrics:

What Happened ?

Key Details

USFDA Approval Update:

• USFDA has granted tentative approval for Pantoprazole Sodium Delayed Release Oral Suspension.
• The approved strength is 40 mg per packet.
• The product approval was granted to Jubilant Generics Limited.
• Manufacturing will be supported by the company’s Roorkee Solid Dosage Manufacturing Facility.
• The approval follows the earlier USFDA Pre-Approval Inspection completed at the facility.
• Final approval is expected after expiry of the patent covering the currently listed Reference Listed Drug (RLD).
• The patent expiry is expected in December 2026.
• The company received the tentative approval on June 25, 2026 at 11:47 AM.

Note:

• A tentative approval confirms that the product satisfies USFDA quality, safety and efficacy requirements but cannot be commercially marketed until the applicable patent or exclusivity period expires and final approval is granted.

Risk Analysis

Summary:

• While the regulatory milestone strengthens Jubilant’s future U.S. pipeline, immediate commercial revenue cannot be recognized until the innovator product’s patent expires and the USFDA issues final approval.

Key Risks:

• Commercial launch is deferred until patent expiry.
• Final USFDA approval remains subject to regulatory requirements at the appropriate time.
• Any extension of patent or exclusivity periods could delay market entry.
• Competitive generic launches following patent expiry may affect market opportunity.

Worst Case:

• If patent-related or regulatory delays occur, commercialization could be postponed beyond the currently expected timeline, delaying potential revenue generation.

Risk Level: Medium

Company Commentary

• Jubilant Generics Limited has received tentative approval from the USFDA for Pantoprazole Sodium Delayed Release Oral Suspension (40 mg per packet).
• The approval follows the earlier successful Pre-Approval Inspection at the Roorkee manufacturing facility.
• Final approval is anticipated after expiry of the Reference Listed Drug patent expected in December 2026.
• The company has disclosed the regulatory update in accordance with SEBI Listing Regulations.